Indications and uses
For the temporary relief of : Chest congestion Cough
For the temporary relief of : Chest congestion Cough
Directions: Adults and children 12 and over Standard Dosage: 1-2 teaspoons every 4 to 6 hours up to 12 teaspoons per day Directions: Children 4- 11 years Standard Dosage: 1 teaspoon every 2-3 hours up to 6 teaspoons per day Directions: Children under 4 years Standard Dosage: Consult a healthcare provider
Drosera rotundifolia 4X.....................Relieves cough
Ipecacuanha 4X................................Relieves chest congestion
Rumex crispus 4X..............................Relieves tickling cough
Antimonium tartaricum 6X..................Relieves chest congestion
Cuprum sulphuricum 6X....................Relieves cough
Spongia tosta 8X..............................Relieves dry cough
Keep out of reach of children
For the temporary relief of :
Stop and ask a doctor if:
If symptoms persist for more than 7 days, comes back, or occurs with fever, rash or headache that lasts. These could be signs of a serious condition. Do not use if known sensitivity to Nectadyn or any of its ingredients exists.
If pregnant or breast-feeding, ask a healthcare provider before use.
Directions: Adults and children 12 and over
Standard Dosage:1-2 teaspoons every 4 to 6 hours up to 12 teaspoons per day
Directions: Children 4- 11 years
Standard Dosage:1 teaspoon every 2-3 hours up to 6 teaspoons per day
Directions: Children under 4 years
Standard Dosage:Consult a healthcare provider
Active ingredients: Drosera rotundifolia 4X, Ipecacuanha 4X, Rumex crispus 4X, Antimonium tartaricum 6X, Cuprum sulphuricum 6X, Spongia tosta 8X.
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 0306390c-dd77-4363-afe0-63c58088b2a1 | Product name | 1 | 20220120 |
| 503ea967-4b9c-48cf-9e87-c7975295849d | Product name | 2 | 20220120 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 50114-8510-1 | 2019-11-27 | C162847 | 48780-1 | 9855d018-dd7b-cd31-e053-dbdaa90ab51a | Nectadyn Cough Syrup |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50114-8510-1 | Nectadyn | 1 in 1 CARTON | SYRUP | 1 | 2 | |
| 50114-8510-1 | Nectadyn | 125 mL in 1 BOTTLE | SYRUP | 125 | 2 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50114-8510 | NECTADYN (DROSERA ROTUNDIFOLIA AND IPECAC AND RUMEX CRISPUS ROOT AND ANTIMONY POTASSIUM TARTRATE AND CUPRIC SULFATE AND SPONGIA OFFICINALIS SKELETON, ROASTED) SYRUP [HEEL INC] | 2 | Legacy NDC, 2 package rows | 20130117_44ebd20f-c157-4717-a3c4-653e48d05f11.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ANTIMONY POTASSIUM TARTRATE | ACTIVE INGREDIENT | DL6OZ476V3 | 2 | |
| CUPRIC SULFATE | ACTIVE INGREDIENT | LRX7AJ16DT | 2 | |
| DROSERA ROTUNDIFOLIA | ACTIVE INGREDIENT | QR44N9XPJQ | 2 | |
| IPECAC | ACTIVE INGREDIENT | 62I3C8233L | 2 | |
| RUMEX CRISPUS ROOT | ACTIVE INGREDIENT | 9N1RM2S62C | 2 | |
| SPONGIA OFFICINALIS SKELETON, ROASTED | ACTIVE INGREDIENT | 1PIP394IID | 2 | |
| ANTIMONY CATION (3+) | ACTIVE MOIETY | 069647RPT5 | 2 | |
| CUPRIC CATION | ACTIVE MOIETY | 8CBV67279L | 2 | |
| DROSERA ROTUNDIFOLIA | ACTIVE MOIETY | QR44N9XPJQ | 2 | |
| IPECAC | ACTIVE MOIETY | 62I3C8233L | 2 | |
| RUMEX CRISPUS ROOT | ACTIVE MOIETY | 9N1RM2S62C | 2 | |
| SPONGIA OFFICINALIS SKELETON, ROASTED | ACTIVE MOIETY | 1PIP394IID | 2 | |
| HONEY | INACTIVE INGREDIENT | Y9H1V576FH | 2 | |
| LEMON OIL | INACTIVE INGREDIENT | I9GRO824LL | 2 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 50114-8510 | 50114-8510-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DROSERA ROTUNDIFOLIA | QR44N9XPJQ | ACTIB |
| IPECAC | 62I3C8233L | ACTIB |
| RUMEX CRISPUS ROOT | 9N1RM2S62C | ACTIB |
| ANTIMONY POTASSIUM TARTRATE | DL6OZ476V3 | ACTIB |
| CUPRIC SULFATE | LRX7AJ16DT | ACTIR |
| SPONGIA OFFICINALIS SKELETON, ROASTED | 1PIP394IID | ACTIB |
| HONEY | Y9H1V576FH | IACT |
| WATER | 059QF0KO0R | IACT |
| SUCROSE | C151H8M554 | IACT |
| LEMON OIL | I9GRO824LL | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PARENTERAL | 18 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYRUP / ORAL | 40 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CONCENTRATE / ORAL | 2.5 mg/5ml | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / INTRAVENOUS | 5 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GEL / TOPICAL | 24 mg | ||
| LEMON OIL | LEMON OIL, COLD PRESSED | I9GRO824LL | SUSPENSION / ORAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAVENOUS | 95 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, COATED / ORAL | 0.8 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION, EXTENDED RELEASE / ORAL | 1000 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | GEL / VAGINAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / SOFT TISSUE | 0.15 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | EMULSION / TOPICAL | 0.06 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYSTEM / TOPICAL | 21 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / VAGINAL | 1225 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SPRAY / TOPICAL | 0.2 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAMUSCULAR | 5 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SOLUTION / ORAL | 13 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LIQUID / ORAL | 162 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | FILM / BUCCAL | 0.22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / ORAL | 388 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | DROPS / AURICULAR (OTIC) | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / TOPICAL | 0.75 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LIQUID / TOPICAL | 0.1 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | JELLY / NASAL | 140 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SYRUP / ORAL | 81 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / TOPICAL | 0.24 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CLOTH / TOPICAL | 0.03 mg/mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAMUSCULAR | 6 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYSTEM / TOPICAL | 4200 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL / TOPICAL | 19.2 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAMUSCULAR | 45 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAMUSCULAR | 0.13 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | OINTMENT / TOPICAL | 0.2 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, EXTENDED RELEASE / TRANSDERMAL | 58.13 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4081b17d-14e8-4aed-ab4e-8d962d417af6 | 44ebd20f-c157-4717-a3c4-653e48d05f11 | 2013-01-15 | Warnings | 4081b17d-14e8-4aed-ab4e-8d962d417af6 44ebd20f-c157-4717-a3c4-653e48d05f11 |
Adverse event summaries are temporarily unavailable. Other product information remains available.